Using an EAE rodent model, investigators found that hippocampal synapse loss could be ameliorated with an NLRP3 inflammasome inhibitor, corresponding with reduced development of memory and cognitive deficits in advanced stages of disease. Here, NLRP3 is linked to Cognitive impairment.